UMC experts discuss how real-time vaccine surveillance works during a pandemic and the role of VigiBase in helping to ensure public safety.

There is much to be gained from using VigiBase to further explore known adverse reactions to drugs, as some may be having more of an impact on patients than first thought.

Despite the difficulties in monitoring drug safety in a country with more than 200 million inhabitants, Brazil's pharmacovigilance system is undergoing profound change.

Duplicate case reports are an obstacle to effective pharmacovigilance but identifying them is a difficult and laborious task.

Duplicate reports are a big problem when it comes to signal detection, but with the help of machine learning and new ways of comparing reports, we may more effectively detect them.

A new short film captures UMC's work to support the pharmacovigilance community as it prepares to take on COVID-19. Filmmaker Matthew Barwick explains the thinking behind it.

What are the implications for signal detection when new approaches to reporting create greater data streams than have ever been present for older medicinal products?

After decades of slow but steady growth, VigiBase has recently entered a new phase of accelerating expansion, driven by a range of converging forces.